Literature DB >> 7549895

Signal transduction through the IL-4 and insulin receptor families.

L M Wang1, A Keegan, M Frankel, W E Paul, J H Pierce.   

Abstract

Activation of tyrosine kinase-containing receptors and intracellular tyrosine kinases by ligand stimulation is known to be crucial for mediating initial and subsequent events involved in mitogenic signal transduction. Receptors for insulin and insulin-like growth factor 1 (IGF-1) contain cytoplasmic tyrosine kinase domains that undergo autophosphorylation upon ligand stimulation. Activation of these receptors also leads to pronounced and rapid tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1) in cells of connective tissue origin. A related substrate, designated 4PS, is similarly phosphorylated by insulin and IGF-1 stimulation in many hematopoietic cell types. IRS-1 and 4PS possess a number of tyrosine phosphorylation sites that are within motifs that bind specific SH2-containing molecules known to be involved in mitogenic signaling such as PI-3 kinase, SHPTP-2 (Syp) and Grb-2. Thus, they appear to act as docking substrates for a variety of signaling molecules. The majority of hematopoietic cytokines bind to receptors that do not possess intrinsic kinase activity, and these receptors have been collectively termed as members of the hematopoietin receptor superfamily. Despite their lack of tyrosine kinase domains, stimulation of these receptors has been demonstrated to activate intracellular kinases leading to tyrosine phosphorylation of multiple substrates. Recent evidence has demonstrated that activation of different members of the Janus family of tyrosine kinases is involved in mediating tyrosine phosphorylation events by specific cytokines. Stimulation of the interleukin 4 (IL-4) receptor, a member of the hematopoietin receptor superfamily, is thought to result in activation of Jak1, Jak3, and/or Fes tyrosine kinases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7549895     DOI: 10.1002/stem.5530130407

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  6 in total

1.  MUTZ-3, a monocytic model cell line for interleukin-4 and lipopolysaccharide studies.

Authors:  H Quentmeier; A Duschl; Z B Hu; B Schnarr; M Zaborski; H G Drexler
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

2.  Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression.

Authors:  L Soon; L Flechner; J S Gutkind; L H Wang; R Baserga; J H Pierce; W Li
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  Infection with Syphacia obvelata (pinworm) induces protective Th2 immune responses and influences ovalbumin-induced allergic reactions.

Authors:  Chesney Michels; Prem Goyal; Natalie Nieuwenhuizen; Frank Brombacher
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  The co-activator-associated arginine methyltransferase 1 (CARM1) gene is overexpressed in type 2 diabetes.

Authors:  Massimo Porta; Cristina Amione; Federica Barutta; Paolo Fornengo; Stefano Merlo; Gabriella Gruden; Luigi Albano; Marco Ciccarelli; Paola Ungaro; Marilena Durazzo; Francesco Beguinot; Paola Berchialla; Franco Cavallo; Marina Trento
Journal:  Endocrine       Date:  2018-09-01       Impact factor: 3.633

5.  Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B.

Authors:  A Z Zhao; H Zhao; J Teague; W Fujimoto; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

6.  Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity.

Authors:  Tetsuya Kubota; Mariko Inoue; Naoto Kubota; Iseki Takamoto; Tomoka Mineyama; Kaito Iwayama; Kumpei Tokuyama; Masao Moroi; Kohjiro Ueki; Toshimasa Yamauchi; Takashi Kadowaki
Journal:  Nat Commun       Date:  2018-11-19       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.